Tech Center 1600 • Art Units: 1633 1634 1638
This examiner grants 29% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17054115 | COMPOSITIONS AND SYSTEMS FOR EX VIVO CELL MODULATION AND METHODS OF USE THEREOF | Final Rejection | Yale University |
| 17762313 | PRODUCTION METHOD FOR INDUCED DOPAMINERGIC NEURONAL PROGENITORS, USING DIRECT REPROGRAMMING | Final Rejection | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 17298071 | METHODS OF USING CD27 ANTIBODIES AS CONDITIONING TREATMENT FOR ADOPTIVE CELL THERAPY | Final Rejection | Celldex Therapeutics, Inc. |
| 17487411 | PERSONALIZED NEOANTIGEN-SPECIFIC ADOPTIVE CELL THERAPIES | Non-Final OA | PACT PHARMA, INC. |
| 17480501 | CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS | Final Rejection | A2 BIOTHERAPEUTICS, INC. |
| 17309451 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | Non-Final OA | Celularity Inc. |
| 17813915 | TRANSPOSON-BASED MODULATION OF GBA1 AND RELATED COMPOSITIONS AND USES THEREOF | Non-Final OA | Aspen Neuroscience, Inc. |
| 17919144 | B CELL IMMUNOMODULATORY THERAPY FOR ACUTE RESPIRATORY DISTRESS SYNDROME | Final Rejection | Holy Cross Hospital, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy